Loading Events
This event has passed.

Free for APS Members

To obtain a free ticket, simply visit the members hub here and get your discount code then purchase a ticket as normal then just add the code to the Promotional Code box.


This event series is split over 4 separate dates; 30th September, 21st October, 5th November and 19th November. Tickets for the first date, 30th September, are available at the bottom of this page.

An Autumn lunch time series of virtual webinars have been organised by Academy of Pharmaceutical Sciences Age Related Medicines Focus Group. These will run each month from September to October, with two speakers and opportunity for questions.
These will include topics on

  • Ameliorating the gut microbiome for longevity and healthy ageing
  • The Gut Microbiome and drug interactions: Biopharmaceutical and oral bioavailability considerations
  • The Ageing Gut: Biopharmaceutical Considerations
  • Mind the Gap Between the Design and Administration of Oral Medicines for Older People
  • Drug Development in Age-Related Medicines and Challenges in Low and Middle Income Countries (LMICs): An academic and pharmaceutical industry perspectiveAs part of the webinars we are also pleased to have a speaker from the MHRA, to talk on “Including the Elderly in Clinical Trials – a Regulatory Viewpoint”.

Four webinars will run, September, October, November.

They will start at 1.00pm and we aim to finish at 2.00pm. There will be an opportunity for Q&A after the talks.

Duration: 60 minutes (20 min. of presentations from each speaker followed by 10 min. of Q&A for each speaker)

You can register for one seminar or for all four.

You will be sent a ZOOM INVITE a day before the event and then one hour before the start. Please click to join.

This webinar series will be of relevance to researchers at all career stages, either in academia or the private sector, who have an interest in the design and development of drug products for the ageing population. The webinars will cover what research questions to ask and what features to prioritise when developing medicinal products for older people.

4th Event; 19th November 2020

Thursday 19th November 2020


APS Series Drug Development in Age-Related Medicines and Challenges in Low and Middle Income Countries (LMICs): An academic and pharmaceutical industry perspective

Aim: Provide an overview of ongoing drug development work in age related medicines and global health challenges drawing on experience from the speakers in academic, clinical, regulatory and pharmaceutical industry.

Presentation Synopsis

Dr Bahijja Raimi-Abraham, Lecturer in Pharmaceutics King’s College London Fight the Fakes Founder and Academic Lead.
Dr Raimi-Abraham’s talk will focus on 4 key areas. Firstly, will start with an overview the challenges in drug development of age-related medicines including as it relates to polypharmacy, taste, disease considerations (from a formulation and regulatory perspective) and clinical trials (regulatory perspective). This will then be followed by examples by way of global case studies of formulation strategies and technologies employed to improve patient acceptability. Thirdly, highlighting challenging in terms of access to medicines and need for in country manufacturing gin LMICs. Dr Raimi-Abraham’s talk will end with a discussion on future perspectives in this area and a call to action.

Professor Trevor Jones, Founder member of Medicines for Malaria Venture (MMV), Director Arix Bioscience plc. Former R&D Director, Wellcome Foundation

Infectious disease …especially in Children…are the main causes of morbidly and mortality in Low- and Middle-Income Countries. Several of these are regarded as “Neglected Diseases”. In recent years a number of Public:Private partnerships have been established to address this; including the development of special paediatric formulations. Malaria is a major infectious disease and many existing drugs are failing due to resistance. Developing combination therapies which are of acceptable palatability is an essential component but the availability of clean water complicates reconstitution. Lack of infrastructure /logistics adds a further complication to the availability of vaccines and therapeutic agents which has led to innovative solutions to develop various types of products to meet the different local conditions

David R Jones 

After spending 8 years in Contract Toxicology and 11 years as a Toxicologist in the Pharmaceutical Industry, I currently work as an Expert Pharmaco-Toxicologist within the Licensing Division of the Medicines and Healthcare products Regulatory Agency (MHRA) in London, whom I joined in 1996. I am a European Registered Toxicologist and a Fellow of the British Toxicology Society. I am also a Chartered Biologist and a Fellow of the Royal Society of Biology.

My current role principally involves assessing nonclinical data for Clinical Trial Authorisation (CTA) Applications and Marketing Authorisation Applications (MAA), both for non-biological and biological products, including advanced therapy medicinal products (ATMPs). A further aspect of my job is to offer scientific advice to companies on behalf of the MHRA. I represented the EU in the ICH revision of the M3 Guideline, on the ICH S10 Guideline, on the Q&A document for ICH S3 (Toxicokinetics) guideline and on the ICH S11 (Nonclinical Studies to Support Paediatric Medicine) guideline.

I work closely with the UK’s National Centre for 3Rs (NC3Rs) and represent the MHRA on a Governmental body dealing with animal welfare.

I am also a guest lecturer at the University of Surrey, the University of Hertford and the University of Leicester and a frequent presenter at conferences around the world.

Professor Trevor Jones

Trevor is a Board member of the life sciences investment company Arix Bioscience plc; and the Oxford based Drug Discovery Company, e-Therapeutics. He was a Director of Allergan Inc. (USA), R&D Director of The Wellcome Foundation and Director General of The ABPI.
He holds honorary degrees and Gold Medals from 7 universities; is a founder member of Medicines for Malaria Venture (MMV); member of The UK Government Regulatory Agency, The Medicines Commission; advisor to the Cabinet Office on the Human Genome project; Chair of the UK Government Advisory Group on Genetics Research; member of the Wales Government Bevan Commission on health; advised the Government of the Netherlands TiPharma on Life Science and is a member of the EU Commission IMI Scientific Advisory Board.

Dr Bahijja Raimi-Abraham

Dr Bahijja Raimi-Abraham is a pharmacist, Lecturer in Pharmaceutics at King’s College London, Founder and Academic Lead of King’s College London Fight the Fakes. She leads her research group “The Raimi-Abraham Group”. Her research to date has been in pharmaceutical materials and innovative manufacture. More recently she has focused her research efforts within the therapeutic and drug development aspects of malaria.

Prior to her current position as Lecturer in Pharmaceutics at King’s College London, Dr. Raimi-Abraham held positions at University College London (UCL) as an Engineering and Physical Sciences Research Council (EPSRC) postdoctoral researcher position and at the European Medicines Agency (EMA) as a seconded Quality National Expert.

Dr. Raimi-Abraham is the first graduate of the University of East Anglia School of Pharmacy to be awarded a Ph.D. and more recently won the Outstanding Woman in STEM Precious Award.

Dr Bahijja Raimi-Abraham is also the host of Monday Science, a weekly podcast which discusses the latest in Science, Health and Technology.

Further details including social media are available here.

1st Event; 30th September 2020

Wednesday 30th September 2020


Ameliorating the gut microbiome for longevity and healthy ageing  ​- Laura McCoubrey​-PhD student UCL School of Pharmacy

It is known that gut microbiome composition dynamically alters over the lifespan, affecting our health as we age. Research is showing that working with, and amending our microbiomes as we age could be the key to a long and healthy life.

The Gut Microbiome and drug interactions: Biopharmaceutical and oral bioavailability considerations – Dr Brendan Griffin-Senior Lecturer in Pharmaceutics – University College Cork

While the ever-increasing scientific breakthroughs have highlighted the influence of the gut microbiome on host health, insights on the role of the microbiota on drug absorption in the gut remain relatively understudied. Elucidating the possible mechanisms by which the gut microbiota might influence or contribute to altered drug bioavailability is thus warranted. In addition, it remains unclear if changes in microbiota diversity, as a result of disease or drug treatment, will impact drug pharmacokinetics in the host.

Laura McCoubrey

Laura is a PhD student at UCL School of Pharmacy investigating how the human microbiome can be ameliorated to prevent and treat disease. She obtained a First Class Honours MPharm degree at The University of Nottingham in 2017, and subsequently worked for two years as a hospital pharmacist in Oxford and East London. Laura joined the Transformative Pharmaceutical Technologies Centre for Doctoral Training at UCL in 2019 and works under the supervision of Professor Abdul Basit, Professor Simon Gaisford, and Dr Mine Orlu. During lockdown, Laura has been writing various reviews and book chapters, and is planning her first year of lab work.

Dr Brendan Griffin

Currently a Senior Lecturer in Pharmaceutics at the School of Pharmacy as University College Cork. His research interests include bio-enabling formulation design, lipid based drug delivery systems, colonic drug delivery and Gut microbiome – drug interactions. He has authored over 70 peer reviewed publications; he is Project Coordinator of the €4m H2020 funded Marie Curie Innovative Training Network (ITN) (www.pearrl.eu) and recently was successfully in leading a new ‘InPharma’ ITN to establish a new fully integrated, animal-free, end-to-end modelling approach in oral drug product development.

2nd Event; 21st October 2020

Wednesday 21st October 2020


The Ageing Gut: Biopharmaceutical Considerations – Francesca Gavins-PhD student-UCL School of Pharmacy

She will discuss how the gastrointestinal tract changes with advancing age, focusing on implications for oral drug delivery. In addition, she will detail key considerations for medicines use in older patients, including higher incidence of polypharmacy and co-morbidities.

Mind the Gap Between the Design and Administration of Oral Medicines for Older People – Neel Desai-UCL School of Pharmacy

His talk discusses how medicines are designed for the many and not the few, which often results in off-label and unlicensed use of medicines in older people. In addition, he described the steps necessary for age-appropriate and personalised medicines design, a process that should begin now, to benefit all.

Francesca Gavins

Francesca is a PhD student and Pharmacist investigating the food effect on gastrointestinal processes. She is an MPharm graduate of UCL School of Pharmacy, completed her pre-registration year in hospital and also works as a locum in community pharmacies, where her interests lie in the appropriate use of medicines. She started the Centre for Doctoral Training at UCL School of Pharmacy in Advanced Therapeutics and Nanomedicines and completed mini-projects in nanofabrication and the dissolution methods at Pfizer. She is now working under the supervision of Dr Orlu and Professor Basit on using food as a tool in the delivery of drugs. She has developed an interest in data science and machine learning tools during lockdown. Francesca enjoys medical writing and has co-authored several papers and book chapters.

Neel Desai

Neel is a PhD candidate at UCL School of Pharmacy. He is a registered pharmacist, who graduated from the School with a First Class Honours MPharm degree, successfully completed his pre-registration year in hospital and now works as a locum community pharmacist. Neel returned to the School, joining the CDT in Advanced Therapeutics and Nanomedicines. He has completed mini-projects in gastrointestinal permeability processes and powder flow at Pfizer. He is now supervised by Dr Mine Orlu and Prof Catherine Tuleu, exploring the use of data to inform the design of age-appropriate medicines. Neel has recently been named an Associate Fellow of the Higher Education Academy, highlighting his ability and passion to teach higher education students.

3rd Event; 5th November 2020

Thursday 5th November 2020


David Jones-MHRA – “Including the Elderly in Clinical Trials – a Regulatory Viewpoint”

The talk will cover a brief summary of clinical trial phases, why elderly are not routinely included in early clinical trials, why it is important to include the elderly in clinical trials and points to consider when including the elderly.

The webinar will start at 1.00pm and we aim to finish at 1.45pm. There will be an opportunity for Q&A after the talks.

Duration: 45 minutes (25 mins of presentations followed by 10 min of Q&A.

Event information



Students and Early careers- £10 per webinar & £30 to attend all 4 webinars

Others- £20 per webinar and £60 to attend all 4 webinars

All prices ex VAT

Supported by the UCL CelebrAGE knowledge exchange initiative. CelebrAGE aims to drive innovation by delivering cross-disciplinary projects into ageing research and related knowledge exchange activities in partnership with UCL researchers and innovators, local communities, local/national charities, industrial enterprises and NHS colleagues.